The MoU signed in 2022 has progressed and culminated in the subsumption of FOGSI-led Manyata initiative’s 20 quality standards across NABH’s Certification programs
Net Profit was at Rs. 10.04 crore, as compared to Rs. 5.12 crore in Q2 FY24, clocking a growth of 96.22%
The program aims to accelerate the development of 6 Indian innovations to improve ease of access to diagnostics and treatment monitoring
_256_384.jpg)
Tyvek with Renewable Attribution is designed to help reduce the carbon footprint
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Subscribe To Our Newsletter & Stay Updated
